Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingye Zhao

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Frontiers in Pharmacology|August 12, 2024
A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastasesYunlin Jiang, Taihang Shao, Mingye Zhao, et al.
Frontiers in Medicine|August 25, 2022
The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trialYuwei Qiu, Wei Gu, Mingye Zhao, et al.
Frontiers in Oncology|August 26, 2022
Adverse outcomes of artificial pneumothorax under right bronchial occlusion for patients with thoracoscopic-assisted oesophagectomy in the prone position versus the semiprone positionQiongzhen Li, Mingye Zhao, Dongjin Wu, et al.
Research Synthesis Methods|February 2, 2026
NMAsurv: An R Shiny application for network meta-analysis based on survival dataTaihang Shao, Mingye Zhao, Fenghao Shi, et al.
BMC Cancer|February 8, 2024
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysisMingye Zhao, Taihang Shao, Hanqiao Shao, et al.
Cost Effectiveness and Resource Allocation : C/E|May 13, 2026
Comparative effectiveness and cost-effectiveness of ALK-positive NSCLC sequential strategies under physician and patient preferencesHao Li, Mingye Zhao, Yue Yin, et al.
Frontiers in Public Health|August 29, 2022
Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in ChinaYinan Ren, Mingye Zhao, Dachuang Zhou, et al.
Cost Effectiveness and Resource Allocation : C/E|September 18, 2024
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspectiveHanqiao Shao, Hongshu Fang, Yuan Li, et al.
International Journal of Technology Assessment in Health Care|November 5, 2025
Cost-Effectiveness Analysis of Blood Cell Separators in Allogeneic Hematopoietic Stem Cell Transplantation: A Perspective from the Chinese Healthcare SystemXiangyan Tang, Hongshu Fang, Mingye Zhao, et al.
Frontiers in Public Health|October 16, 2023
Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspectiveYunlin Jiang, Mingye Zhao, Jiayi Xi, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Frontiers in Pharmacology|August 12, 2024
A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastasesYunlin Jiang, Taihang Shao, Mingye Zhao, et al.
Frontiers in Medicine|August 25, 2022
The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trialYuwei Qiu, Wei Gu, Mingye Zhao, et al.
Frontiers in Oncology|August 26, 2022
Adverse outcomes of artificial pneumothorax under right bronchial occlusion for patients with thoracoscopic-assisted oesophagectomy in the prone position versus the semiprone positionQiongzhen Li, Mingye Zhao, Dongjin Wu, et al.
Research Synthesis Methods|February 2, 2026
NMAsurv: An R Shiny application for network meta-analysis based on survival dataTaihang Shao, Mingye Zhao, Fenghao Shi, et al.
BMC Cancer|February 8, 2024
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysisMingye Zhao, Taihang Shao, Hanqiao Shao, et al.
Cost Effectiveness and Resource Allocation : C/E|May 13, 2026
Comparative effectiveness and cost-effectiveness of ALK-positive NSCLC sequential strategies under physician and patient preferencesHao Li, Mingye Zhao, Yue Yin, et al.
Frontiers in Public Health|August 29, 2022
Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in ChinaYinan Ren, Mingye Zhao, Dachuang Zhou, et al.
Cost Effectiveness and Resource Allocation : C/E|September 18, 2024
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspectiveHanqiao Shao, Hongshu Fang, Yuan Li, et al.
International Journal of Technology Assessment in Health Care|November 5, 2025
Cost-Effectiveness Analysis of Blood Cell Separators in Allogeneic Hematopoietic Stem Cell Transplantation: A Perspective from the Chinese Healthcare SystemXiangyan Tang, Hongshu Fang, Mingye Zhao, et al.
Frontiers in Public Health|October 16, 2023
Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspectiveYunlin Jiang, Mingye Zhao, Jiayi Xi, et al.
Pageof 4